CIrCuLAting Dna ESr1 Gene Mutations Analysis

NACompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

December 7, 2017

Primary Completion Date

December 22, 2022

Study Completion Date

December 22, 2022

Conditions
Breast Cancer
Interventions
DIAGNOSTIC_TEST

next-generation sequencing (NGS)

ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.

Trial Locations (10)

51100

Institut Jean Godinot, Reims

Polyclinique de Courlancy, Reims

54509

Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy

57070

Hôpital Claude Bernard, Metz

57085

CHR Metz-Thionville, Metz

67000

Polyclinique de l'Orangerie, Strasbourg

67085

Clinique Saint Anne, Strasbourg

67091

CHU Strasbourg, Strasbourg

76038

Centre Henri Becquerel, Rouen

Unknown

Centre d'oncologie Gentilly, Nancy

All Listed Sponsors
lead

Institut de Cancérologie de Lorraine

OTHER

NCT03318263 - CIrCuLAting Dna ESr1 Gene Mutations Analysis | Biotech Hunter | Biotech Hunter